French comprehensive cancer centre contributing clinical oncology cohorts, immunophenotyping, and precision diagnostics expertise to European research consortia.
Centre Léon Bérard is a leading French comprehensive cancer centre in Lyon, specializing in clinical oncology, immuno-oncology, and translational cancer research. They contribute clinical cohorts, patient data, and tumour biobanking expertise to large European research programmes spanning rare cancers, immunotherapy monitoring, and next-generation sequencing diagnostics. Their work bridges the gap between laboratory findings and bedside treatment across both adult and paediatric cancers, with particular depth in sarcoma, head and neck cancers, and immunophenotyping.
IMMUcan (integrated immunoprofiling across major cancer types), QUALITOP (quality of life after immunotherapy), and SELNET (rare tumour clinical care) all involve immune-related cancer research.
EJP RD, SELNET (sarcoma as model for rare tumours), ERICA (rare disease coordination), and Instand-NGS4P (common and rare cancers) demonstrate sustained engagement with rare disease frameworks.
Instand-NGS4P focuses on standardised NGS workflows for personalised therapy, while IMMUcan applies deep cytometry and RNA sequencing for immunoprofiling.
FORTEe targets exercise interventions for childhood cancer patients, and Instand-NGS4P explicitly covers paediatric cancer diagnostics.
HEADSpAcE studies head and neck cancer genetics across South America and Europe, while IMMUcan includes head and neck among its target cancer types.
PROTECT-trial compares proton versus photon therapy for esophageal cancer in a trimodality strategy.
CLB's early H2020 engagement (2019) centred on rare disease data sharing, FAIR principles, sarcoma diagnostics, and foundational omics and immunoprofiling work. By 2020-2021, their focus shifted decisively toward precision diagnostics — standardised NGS workflows, pharmacogenetics, gene panels, and e-reporting — alongside new clinical domains like paediatric exercise oncology and proton therapy. The trajectory shows a centre moving from broad translational research participation toward applied precision medicine and treatment quality outcomes.
CLB is moving toward standardised precision medicine pipelines (NGS, pharmacogenetics) and patient quality-of-life outcomes, making them an increasingly relevant partner for projects needing clinical validation of diagnostic workflows.
CLB operates exclusively as a consortium participant — they have never coordinated an H2020 project, indicating they contribute specialist clinical expertise rather than driving project management. With 258 unique partners across 44 countries, they plug into very large multinational consortia (most of their projects involve dozens of partners), acting as a trusted clinical site that provides patient cohorts and biobank access. Their consistent participant role and broad partner network suggest they are a reliable, low-friction collaborator that integrates well into existing consortium structures.
CLB has collaborated with 258 distinct partners across 44 countries, reflecting deep integration into Europe's largest cancer research networks. Their partnerships span well beyond the EU, with the HEADSpAcE project extending into South America, giving them genuinely global clinical research reach.
CLB stands out as one of France's 20 designated comprehensive cancer centres (Centres de Lutte Contre le Cancer), giving them direct access to large, diverse patient populations and clinical-grade biobanking infrastructure. Unlike university hospitals that spread across many medical fields, CLB is 100% focused on cancer — every project, every dataset, every clinical resource is oncology. For consortium builders, this means a partner that brings real patient cohorts, tumour samples, and clinical trial infrastructure without the overhead of navigating a general hospital bureaucracy.
